Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents

Junko Ohkanda, Frederick S. Buckner, Jeffrey W. Lockman, Kohei Yokoyama, Dora Carrico, Richard Eastman, Kate De Luca-Fradley, Wendy Davies, Simon L. Croft, Wesley C. Van Voorhis, Michael H. Gelb, Saïd M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

On the basis of the structure of the CVIM tetrapeptide substrate of mammalian protein farnesyltransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their inhibition activity against Trypanosoma brucei protein farnesyltransferase (TbPFT) was evaluated. Peptidomimetics where the 5-position of the imidazole ring was linked to the hydrophobic scaffold showed over 70% inhibition activity at 50 nM in the enzyme assay, whereas the corresponding C-4 regioisomers were less potent. The ester prodrug 23 was found to be a potent inhibitor against cultured Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense cells with ED50 values of 0.025 and 0.0026 μM, respectively. Furthermore, introducing a second imidazole group into 23 led to 31, which showed the highest inhibition activity against the parasite with an ED50 of 0.0015 μM. The potency of the TbPFT inhibitors and the cytotoxicity of the corresponding esters to T. brucei cells were shown to be highly correlated. These studies validate TbPFT as a target for the development of novel therapeutics against African sleeping sickness.

Original languageEnglish (US)
Pages (from-to)432-445
Number of pages14
JournalJournal of Medicinal Chemistry
Volume47
Issue number2
DOIs
StatePublished - Jan 15 2004

Fingerprint

Peptidomimetics
Trypanosoma brucei brucei
Esters
Prodrugs
Cytotoxicity
Trypanosoma brucei rhodesiense
Scaffolds
African Trypanosomiasis
Assays
Enzyme Assays
p21(ras) farnesyl-protein transferase
Parasites
Substrates
Enzymes
imidazole

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents. / Ohkanda, Junko; Buckner, Frederick S.; Lockman, Jeffrey W.; Yokoyama, Kohei; Carrico, Dora; Eastman, Richard; De Luca-Fradley, Kate; Davies, Wendy; Croft, Simon L.; Van Voorhis, Wesley C.; Gelb, Michael H.; Sebti, Saïd M.; Hamilton, Andrew.

In: Journal of Medicinal Chemistry, Vol. 47, No. 2, 15.01.2004, p. 432-445.

Research output: Contribution to journalArticle

Ohkanda, J, Buckner, FS, Lockman, JW, Yokoyama, K, Carrico, D, Eastman, R, De Luca-Fradley, K, Davies, W, Croft, SL, Van Voorhis, WC, Gelb, MH, Sebti, SM & Hamilton, A 2004, 'Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents', Journal of Medicinal Chemistry, vol. 47, no. 2, pp. 432-445. https://doi.org/10.1021/jm030236o
Ohkanda, Junko ; Buckner, Frederick S. ; Lockman, Jeffrey W. ; Yokoyama, Kohei ; Carrico, Dora ; Eastman, Richard ; De Luca-Fradley, Kate ; Davies, Wendy ; Croft, Simon L. ; Van Voorhis, Wesley C. ; Gelb, Michael H. ; Sebti, Saïd M. ; Hamilton, Andrew. / Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents. In: Journal of Medicinal Chemistry. 2004 ; Vol. 47, No. 2. pp. 432-445.
@article{c9c6dd627d6e42a3a71fa0f825382ae6,
title = "Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents",
abstract = "On the basis of the structure of the CVIM tetrapeptide substrate of mammalian protein farnesyltransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their inhibition activity against Trypanosoma brucei protein farnesyltransferase (TbPFT) was evaluated. Peptidomimetics where the 5-position of the imidazole ring was linked to the hydrophobic scaffold showed over 70{\%} inhibition activity at 50 nM in the enzyme assay, whereas the corresponding C-4 regioisomers were less potent. The ester prodrug 23 was found to be a potent inhibitor against cultured Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense cells with ED50 values of 0.025 and 0.0026 μM, respectively. Furthermore, introducing a second imidazole group into 23 led to 31, which showed the highest inhibition activity against the parasite with an ED50 of 0.0015 μM. The potency of the TbPFT inhibitors and the cytotoxicity of the corresponding esters to T. brucei cells were shown to be highly correlated. These studies validate TbPFT as a target for the development of novel therapeutics against African sleeping sickness.",
author = "Junko Ohkanda and Buckner, {Frederick S.} and Lockman, {Jeffrey W.} and Kohei Yokoyama and Dora Carrico and Richard Eastman and {De Luca-Fradley}, Kate and Wendy Davies and Croft, {Simon L.} and {Van Voorhis}, {Wesley C.} and Gelb, {Michael H.} and Sebti, {Sa{\"i}d M.} and Andrew Hamilton",
year = "2004",
month = "1",
day = "15",
doi = "10.1021/jm030236o",
language = "English (US)",
volume = "47",
pages = "432--445",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents

AU - Ohkanda, Junko

AU - Buckner, Frederick S.

AU - Lockman, Jeffrey W.

AU - Yokoyama, Kohei

AU - Carrico, Dora

AU - Eastman, Richard

AU - De Luca-Fradley, Kate

AU - Davies, Wendy

AU - Croft, Simon L.

AU - Van Voorhis, Wesley C.

AU - Gelb, Michael H.

AU - Sebti, Saïd M.

AU - Hamilton, Andrew

PY - 2004/1/15

Y1 - 2004/1/15

N2 - On the basis of the structure of the CVIM tetrapeptide substrate of mammalian protein farnesyltransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their inhibition activity against Trypanosoma brucei protein farnesyltransferase (TbPFT) was evaluated. Peptidomimetics where the 5-position of the imidazole ring was linked to the hydrophobic scaffold showed over 70% inhibition activity at 50 nM in the enzyme assay, whereas the corresponding C-4 regioisomers were less potent. The ester prodrug 23 was found to be a potent inhibitor against cultured Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense cells with ED50 values of 0.025 and 0.0026 μM, respectively. Furthermore, introducing a second imidazole group into 23 led to 31, which showed the highest inhibition activity against the parasite with an ED50 of 0.0015 μM. The potency of the TbPFT inhibitors and the cytotoxicity of the corresponding esters to T. brucei cells were shown to be highly correlated. These studies validate TbPFT as a target for the development of novel therapeutics against African sleeping sickness.

AB - On the basis of the structure of the CVIM tetrapeptide substrate of mammalian protein farnesyltransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their inhibition activity against Trypanosoma brucei protein farnesyltransferase (TbPFT) was evaluated. Peptidomimetics where the 5-position of the imidazole ring was linked to the hydrophobic scaffold showed over 70% inhibition activity at 50 nM in the enzyme assay, whereas the corresponding C-4 regioisomers were less potent. The ester prodrug 23 was found to be a potent inhibitor against cultured Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense cells with ED50 values of 0.025 and 0.0026 μM, respectively. Furthermore, introducing a second imidazole group into 23 led to 31, which showed the highest inhibition activity against the parasite with an ED50 of 0.0015 μM. The potency of the TbPFT inhibitors and the cytotoxicity of the corresponding esters to T. brucei cells were shown to be highly correlated. These studies validate TbPFT as a target for the development of novel therapeutics against African sleeping sickness.

UR - http://www.scopus.com/inward/record.url?scp=9144248974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144248974&partnerID=8YFLogxK

U2 - 10.1021/jm030236o

DO - 10.1021/jm030236o

M3 - Article

VL - 47

SP - 432

EP - 445

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 2

ER -